Literature DB >> 15364888

Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death.

Fred S Apple1, Maryann M Murakami, Lesly A Pearce, Charles A Herzog.   

Abstract

BACKGROUND: In patients with end-stage renal disease (ESRD), the ability of single and multiple biomarker monitoring to predict adverse outcomes has not been well established. This study determined the prognostic value of multiple biomarkers for all-cause death over 2 years in 399 ESRD patients.
METHODS: The risk of all-cause death was determined by use of multiple biomarkers based on concentrations for a reference population (normal) and cutoffs based on tertile distributions in the ESRD group. Biomarkers studied included N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP; Dade Behring and Roche assays), and cardiac troponin T (cTnT; Roche) and I (cTnI; Dade Behring and Beckman Coulter assays). Relative risks of death were estimated and survival curves computed.
RESULTS: A total of 101 deaths occurred during 594 patient-years of follow-up. Increased NT-proBNP concentrations were not predictive of death on the basis of the normal cutoffs. However, tertile analysis of NT-proBNP was significantly predictive of death and had a ROC area under the curve equivalent to or better than any of the other biomarkers. Biomarkers independently predictive of survival were hsCRP (P <0.001, either assay), cTnT (P <0.05), and cTnI (Dade, P <0.05). Two-year mortality rates were 6% (n = 45) with normal hsCRP, cTnI, and cTnT concentrations; 19% (n = 173) with increased hsCRP or cTnT and normal cTnI; 44% (n = 160) with both hsCRP and cTnT increased and normal cTnI; 61% (n = 21) with increased cTnI (Dade) or 47% (n = 74) with increased cTnI (Beckman) regardless of hsCRP or cTnT concentrations. Defined by the normal cutoffs, increased concentrations of biomarkers were present in various proportions of the 399 patients with ESRD: NT-proBNP, 99%; hsCRP, 46% (both Roche and Dade assays); cTnT, 85%; cTnI, 19% (Beckman assay) and 5% (Dade assay).
CONCLUSIONS: Although mechanisms likely vary for causation, increased plasma hsCRP, cTnT, and cTnI above the cutoffs for our reference (normal) population were all independently predictive of subsequent death in ESRD patients. Tertile analysis for NT-proBNP also demonstrated prognostic value.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364888     DOI: 10.1373/clinchem.2004.035741

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  40 in total

1.  Raised plasma N-terminal pro-B-type natriuretic peptide concentrations predict mortality and cardiac disease in end-stage renal disease.

Authors:  R Sharma; D C Gaze; D Pellerin; R L Mehta; H Gregson; C P Streather; P O Collinson; S J D Brecker
Journal:  Heart       Date:  2006-10       Impact factor: 5.994

2.  Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay.

Authors:  Meghana R Gaiki; Maria V DeVita; Michael F Michelis; Georgia Panagopoulos; Jordan L Rosenstock
Journal:  Int Urol Nephrol       Date:  2012-02-05       Impact factor: 2.370

3.  Association between N-terminal pro-brain natriuretic peptide and acute ischemic stroke in patients on chronic hemodialysis.

Authors:  Yong Kyun Kim; Seok Joon Shin; Sang-Hyun Ihm; Chan Seok Park; Hee-Yeol Kim; Young-Du Kim; Dong Suk Shim; Ho Cheol Song; Chul Woo Yang; Yong-Soo Kim; Euy Jin Choi
Journal:  Int Urol Nephrol       Date:  2009-12-29       Impact factor: 2.370

4.  Biomarkers and cardiac disease in patients with end-stage renal disease on dialysis.

Authors:  Peter E Hickman
Journal:  Clin Biochem Rev       Date:  2011-05

Review 5.  Troponin: the biomarker of choice for the detection of cardiac injury.

Authors:  Luciano Babuin; Allan S Jaffe
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

6.  Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T.

Authors:  R Sharma; D C Gaze; D Pellerin; R L Mehta; H Gregson; C P Streather; P O Collinson; S J D Brecker
Journal:  Heart       Date:  2005-10-10       Impact factor: 5.994

Review 7.  Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?

Authors:  Thanat Chaikijurajai; Hernan Rincon Choles; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-09-17

8.  Biomarkers in predicting mortality and treatment in hemodialysis patients.

Authors:  Angela Yee-Moon Wang
Journal:  F1000 Med Rep       Date:  2009-03-17

9.  Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.

Authors:  Martin J Landray; Jonathan R Emberson; Lisa Blackwell; Tanaji Dasgupta; Rosita Zakeri; Matthew D Morgan; Charlie J Ferro; Susan Vickery; Puja Ayrton; Devaki Nair; R Neil Dalton; Edmund J Lamb; Colin Baigent; Jonathan N Townend; David C Wheeler
Journal:  Am J Kidney Dis       Date:  2010-10-30       Impact factor: 8.860

Review 10.  Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.

Authors:  Usama Elewa; Maria Dolores Sanchez-Niño; Catalina Martin-Cleary; Beatriz Fernandez-Fernandez; Jesus Egido; Alberto Ortiz
Journal:  Int Urol Nephrol       Date:  2012-09-11       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.